Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  adult primary hepatocellular carcinoma
Stage/Subtype:  adult primary hepatocellular carcinoma
Trial Type:  Screening
Trial Status:  Active
Results 1-6 of 6 for your search:
Start Over
Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study
Phase: No phase specified
Type: Screening
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: KMUH-IRB-960012, NCT00629421
Study of PIVKA-II and AFP Measurement in Surveillance Program for Early Detection of Hepatocellular Carcinoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Screening
Status: Active
Age: 20 to 75
Sponsor: Other
Protocol IDs: AFP-PIVKA, NCT01277653
Screening for Liver Cancer With CT vs. Ultrasound in Patients With Advanced Liver Disease
Phase: No phase specified
Type: Diagnostic, Health services research, Screening
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 3034-A, NCT01350167
AFP - L3% and DCP as Screening Marker for a Hepatocellular Carcinoma in Patients With Cirrhosis of the Liver
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Screening
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: HCC3, DRKS00000811, NCT01361061
PROLIFICA - West African Treatment Cohort for Hepatitis B
Phase: No phase specified
Type: Natural history/Epidemiology, Screening
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: WMDH-P34114, NCT02129829
A Protocol of the Canadian Prospective Study for Hepatocellular Carcinoma Surveillance Using Biomarkers
Phase: No phase specified
Type: Screening
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: WLS 13-6926, NCT02272504
Start Over